Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: A retrospective review of 65 Japanese patients

International Journal of Clinical Oncology

Volumn 14, Issue 6, 2009, Pages 513-517

  Tamiya, Akihiro ^a   Yamazaki, Kentaro ^a   Boku, Narikazu ^a   MacHida, Nozomu ^a   Kojima, Takashi ^a   Taku, Keisei ^a   Yasui, Hirofumi ^a   Fukutomi, Akira ^a   Hironaka, Shuichi ^a   Onozawa, Yusuke ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Bevacizumab; Colorectal cancer; Safety

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BRAIN INFARCTION; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; INTERSTITIAL PNEUMONIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEINURIA; RECTUM PERFORATION; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SMALL INTESTINE PERFORATION; STOMATITIS; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 72949103325     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-009-0911-6     Document Type: Article

References (16)

1. M. Toi T. Matsumoto H. Bando 2001 Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications Lancet Oncol 2 667 673 10.1016/S1470-2045(01)00556-3 1:CAS:528:DC%2BD3MXovVWntLw%3D 11902537 (Pubitemid 33085812)
2. H.P. Gerber N. Ferara 2005 Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 671 680 1:CAS:528:DC%2BD2MXhtVWnsb0%3D 15705858
3. H. Hurwitz L. Fehrenbacher W. Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
4. K. Miller M. Wang J. Galow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer New Engl J Med 357 2666 2676 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 18160686
5. A.B. Sandler R. Gray M.C. Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 335 2542 2550 10.1056/NEJMoa061884 (Pubitemid 44917502)
6. L.B. Saltz S. Clarke E. Diaz-Rubio, et al. 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D 18421054
7. F.F. Kabbinavar J. Hambleton R.D. Mass, et al. 2005 Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 3706 3712 10.1200/JCO.2005.00.232 1:CAS:528:DC%2BD2MXlslWntro%3D 15867200 (Pubitemid 46252465)
8. B.J. Giantonio P.J. Catalano N.J. Meropol, et al. 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544 10.1200/JCO.2006.09.6305 1:CAS:528:DC%2BD2sXlsVyntbc%3D 17442997 (Pubitemid 46733080)
9. Hedrick E, Kozloff M, Hainsworth J, et al. (2006) Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). ASCO Annual Meeting (abstract #3536), Atlanta, USA, June 2-6, 2006
10. Van Cutsem E, Michael M, Berry S, et al. (2007) Preliminary safety and efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI, and capecitabine for mCRC: first BEATrial. Gastrointestinal Cancer Symposium (abstract #346)
11. Flynn PJ, Sugrue MM, Purdie DM, et al. (2008) Serious bleeding events are uncommon in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: results from the BRiTE observational Cohort Study. Gastrointestinal Cancer Symposium (abstract #346)
12. Kozloff M, Hainsworth J, Badarinath S, et al. (2007) Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer treated with bevacizumab (BV) plus chemotherapy. Gastrointestinal Cancer Symposium (abstract #364)
13. Sugrue MM, Kozloff M, Hainsworth J, et al. (2007) Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: results from the BRiTE registry. Gastrointestinal Cancer Symposium (abstract #345)
14. F. Kabbinavar A. Shah 2008 Guidelines for the management of side effects of bevacizumab in patients with colorectal cancer Cancer Ther 6 327 339 1:CAS:528:DC%2BD1cXht1KgtrrJ
15. A.B. Sandler J.H. Schiller R. Gray, et al. 2009 Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab J Clin Oncol 27 1405 1412 10.1200/JCO.2008.16.2412 1:CAS:528:DC%2BD1MXksF2hsro%3D 19224857
16. F.A. Scappaticci J.R. Skillings S.N. Holden, et al. 2007 Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 1232 1239 10.1093/jnci/djm086 17686822 (Pubitemid 47299901)